Synthetic lipopeptide MALP-2 inhibits intracellular growth of Mycobacterium bovis BCG in alveolar macrophages-preliminary data.
Alveolar macrophages (AM) are the primary target cell of the lung for inhaled mycobacterial pathogens. We investigated the effect of the synthetic lipopeptide MALP-2 on the interaction between AM from rats and Mycobacterium bovis BCG. AM were infected with M. bovis BCG at a multiplicity of infection (MOI) of 10 and then cultured in medium alone or medium supplemented with either synthetic macrophage activating lipopeptide-2 (MALP-2), or IFN-gamma, or both. Mycobacterial CFU were counted on days 3 and 7 and cell-free supernatants were collected for cytokine measurements. Treatment of macrophages with MALP-2 led to reduced bacterial loads by day 3 and 7 post-infection and at the same time enhanced the release of TNF-alpha, IL-6 und IL-10 compared to non-stimulated, M. bovis BCG-infected AM. Macrophages co-treated with MALP-2 and IFN-gamma or IFN-gamma in the absence of MALP-2 limited the growth of M. bovis BCG only by day 3, but not day 7 post-stimulation. Our data show that MALP-2 is effective in decreasing bacterial loads in lung sentinel cells.
Jörgens
Grit
G
Institute for Functional and Applied Anatomy, Medical School of Hannover, Hannover, Germany.
Bange
Franz-Christoph
FC
Mühlradt
Peter F
PF
Pabst
Reinhard
R
Maus
Ulrich A
UA
Tschernig
Thomas
T
D000818:Animals; D015169:Colony Count, Microbial; D016207:Cytokines / Q000032:analysis; D007371:Interferon-gamma / Q000494:pharmacology; D055666:Lipopeptides / Q000138:chemical synthesis / Q000494:pharmacology*; D008168:Lung / Q000382:microbiology / Q000473:pathology; D016676:Macrophages, Alveolar / Q000382:microbiology*; D009163:Mycobacterium bovis / Q000187:drug effects* / Q000254:growth & development; D051381:Rats; D014376:Tuberculosis / Q000382:microbiology / Q000473:pathology
D016207:Cytokines; D055666:Lipopeptides; D007371:Interferon-gamma; C106335:macrophage stimulatory lipopeptide 2